Damora Therapeutics DMRA
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 99th percentile, 5-year average -7.0x
#940 of 2990 stocks by PE (1 = cheapest)
Near the top of its 5-year range · 90th percentile, 5-year average 2.4x
#4022 of 5329 stocks by PB (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 3.66 | – | 2.42 | 90% (pricier than usual) | #4022 of 5329 (1 = cheapest) |
| PE | 12.63 | -9.52 | -6.97 | 99% (pricier than usual) | #940 of 2990 (1 = cheapest) |
| PS | – | – | 0.00 | – | – |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on DMRA.
Sign in to join the discussion.